|Table of Contents|

The efficacy and safety of azacitidine combined with CAG regimen in the treatment of elderly acute myeloid leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2879-2883
Research Field:
Publishing date:

Info

Title:
The efficacy and safety of azacitidine combined with CAG regimen in the treatment of elderly acute myeloid leukemia
Author(s):
LIANG Bo
Hematology Department,Xinxiang Central Hospital,Henan Xinxiang 453000,China.
Keywords:
CAG regimen; azacitidine; elderly acute myeloid leukemia; clinical effect; hematological indicators; safety
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2023.15.021
Abstract:
Objective:To investigate the clinical therapeutic effect of azacytoside combined with CAG regimen in the treatment of elderly acute myeloid leukemia (AML),and the influence and safety of hematologic indexes after treatment.Methods:A total of 101 elderly AML patients admitted to our hospital from January 2019 to January 2022 were randomly divided into a combined group (n=55) and a control group (n=46).Elderly AML patients in the combination group were treated with azacytoside combined with CAG regimen,while elderly AML patients in the control group were treated with single CAG regimen.The clinical therapeutic effect,blood indexes,neutrophil recovery time,platelet infusion volume,platelet recovery time,safety and quality of life scores of the two groups of elderly AML patients were compared.Results:After 28 days of treatment,the total remission rate of elderly AML patients in the combined group was higher than that in the control group (90.91% vs 63.04%) (P＜0.05).The white blood cell count and platelet count of the combined group were higher than those of the control group,while the hemoglobin of the combined group was lower than that of the control group (P＜0.05).The platelet transfusion volume,platelet recovery time and neutrophil recovery time of the combined group were significantly lower than those of the control group (P＜0.05).There was no significant difference in the total adverse reactions between combined group and control group (14.55% vs 15.22%) (P＞0.05).The quality of life score of elderly AML patients in combined group was higher than that in control group (P＜0.05).The 1-year survival rate of the combined group was 72.73%（40/55）,which was significantly higher than that of the control group 52.17%（24/46）(P＜0.05).Conclusion:CAG regimen combined with azacitidine therapy has high safety in elderly AML patients,and can improve patients' hematological indexes,reduce platelet transfusion volume,and shorten platelet recovery time and neutrophil recovery time.Combination therapy may also increase survival time.

References:

［1］娄典,刘利,秦炜炜.维奈克拉联合阿扎胞苷治疗老年初治急性髓系白血病的临床分析［J］.中国肿瘤临床,2022,49(15):775-780. LOU D,LIU L,QIN WW.Clinical analysis of vinclair combined with azacytidine in the treatment of newly diagnosed acute myeloid leukemia in the elderly ［J］.China Cancer Clinic,2022,49(15):775-780.
［2］ANDREANI G,CAMERLO S,PAUTASSO M,et al.Phenotypical heterogeneity of acute myeloid leukemia in the elderly:a clue for a personalized therapy［J］.Leuk Lymphoma,2020,61(5):1234-1237.
［3］DEL GALY AS,MAROUF A,RAFFOUX E,et al.Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes:myth and reality［J］.Leukemia,2021,35(1):225-228.
［4］LAI B,MU Q,ZHANG Y,et al.Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen［J］.Hematology,2021,26(1):751-757.
［5］ZHANG CL,FENG R,LI JT,et al.A new tool for comprehensive geriatric assessment in elderly patients with acute myeloid leukemia:a pilot study from China［J］.Chin Med J (Engl),2020,133(4):381-387.
［6］FAN T,QUAN RC,LIU WY,et al.Arsenic-containing qinghuang powder (青黄散) is an alternative treatment for elderly acute myeloid leukemia patients refusing low-intensity chemotherapy［J］.Chin J Integr Med,2020,26(5):339-344.
［7］OWATTANAPANICH W,UTCHARIYAPRASIT E,TANTIWORAWIT A,et al.Improved survival of elderly-fit patients with acute myeloid leukemia requiring intensive therapy:3-year multicenter analysis from TALWG［J］.Clin Lymphoma Myeloma Leuk,2018,18(12):e509-e514.
［8］中华医学会血液学分会白血病淋巴瘤学组.复发难治性急性髓系白血病中国诊疗指南(2017年版)［J］.中华血液学杂志,2017,038(003):183-184. Leukemia and Lymphoma Group,Hematology Branch,Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of recurrent and refractory acute myeloid leukemia (2017 edition)［J］ .Chinese Journal of Hematology,2017,038(003):183-184.
［9］WEINBERG OK,HASSERJIAN RP,BARABAN E,et al.Clinical,immunophenotypic,and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation:a study from the bone marrow pathology group［J］.Mod Pathol,2019,32(9):1373-1385.
［10］宗李红,吴小霞,张剑,等.维奈克拉联合阿扎胞苷治疗难治复发性急性髓系白血病疗效及安全性分析［J］.中华血液学杂志,2021,42(10):861-864. ZONG LH,WU XX,ZHANG J,et al.Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia［J］.Chin J Hematol,2021,42(10):861-864.
［11］乐丽霞，李丹红，张思源，等.老年急性髓系白血病的治疗进展［J］.中国当代医药，2022，29（20）：35-39. LE LX,LI DH,ZHANG SY,et al.Advances in the treatment of acute myeloid leukemia in the elderly［J］.China Modern Medicine，2022，29（20）：35-39.
［12］PARK S,KIM YJ,HUH HJ,et al.Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia［J］.Hematology,2021,26(1):904-913.
［13］CANAANI J,BEOHOU E,LABOPIN M,et al.Impact of FAB classification on predicting outcome in acute myeloid leukemia,not otherwise specified,patients undergoing allogeneic stem cell transplantation in CR1:An analysis of 1 690 patients from the acute leukemia working party of EBMT［J］.Am J Hematol,2017,92(4):344-350.
［14］齐瑶,赵明峰,肖霞,等.地西他滨联合减量FLAG方案治疗老年高危急性髓系白血病患者的临床疗效观察［J］.中国实验血液学杂志,2020,28(05):1440-1444. QI Y，ZHAO MF,XIAO X,et al.Clinical efficacy of descitabine combined with reduced FLAG regimen in the treatment of elderly patients with high-risk acute myeloid leukemia ［J］.Chinese Journal of Experimental Hematology,2020,28(05):1440-1444.
［15］KIYOI H,YAMAGUCHI H,MAEDA Y,et al.JSH practical guidelines for hematological malignancies,2018:I.leukemia-1.acute myeloid leukemia (AML)［J］.Int J Hematol,2020,111(5):595-613.
［16］张倩倩,封亚丽,董雯,等.黄芪水煎剂联合地西他滨、CAG方案治疗老年急性髓系白血病的临床研究［J］.南京中医药大学学报,2022,38(03):199-203，211. ZHANG QQ,FENG YL,DONG W,et al.Clinical study on the treatment of senile acute myeloid leukemia with astragalus decoction combined with dicitabine and CAG regimen ［J］.Journal of Nanjing University of Traditional Chinese Medicine,2022,38 (03):199-203，211.
［17］WANG D,HE K,SROUSSI H,et al.Oral myeloid sarcoma as an uncommon manifestation of acute myeloid leukemia:A case series and review of the literature［J］.J Am Dent Assoc,2021,152(5):393-400.
［18］BORLENGHI E,PAGANI C,ZAPPASODI P,et al.Secondary acute myeloid leukaemia in elderly patients:Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions.An analysis of 280 patients by the network rete ematologica lombarda (REL)［J］.Am J Hematol,2018,93(2):E54-E57.
［19］POIR X,LABOPIN M,POLGE E,et al.Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication:a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation［J］.Haematologica,2018,103(2):256-265.
［20］KHNKE T,BCKLEIN V,RECHKEMMER S,et al.Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia,amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction［J］.Haematologica,2019,104(11):e510-e513.
［21］REDDY P,DAVIES S,MAJHAIL N,et al.In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults"［J］.Blood Adv,2020,4(21):5431-5432.

Memo

Memo:
-
Last Update: 2023-06-30